The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Background: 

Lumiracoxib is a novel selective cyclooxygenase-2 (COX-2) inhibitor in development for the treatment of chronic and acute pain. Methods: 

This randomized, double-blind multicentre study enrolled 180 patients (aged 18–80 years) with moderate-to-severe pain (≥2 on a 4-point categorical scale) within 48 h of unilateral total knee or total hip arthroplasty. Patients were randomized to receive lumiracoxib 400 mg once daily (n = 60), placebo (n = 60) or naproxen 500 mg twice daily (n = 60). The study consisted of a 12-h single-dose phase followed by a multiple-dose phase (up to 96 h or until discontinuation). The primary efficacy measure was the summed (time-weighted) pain intensity difference over 0–8 h after the first dose (SPID-8). Results: 

Lumiracoxib and naproxen were comparable and both treatments were superior to placebo for the primary efficacy measure, SPID-8. Both treatments were generally similar and also superior to placebo for the secondary efficacy measures during both the single- and multiple-dose phases for up to 96 h. Both active treatments were well tolerated. Conclusion: 

Lumiracoxib is an effective alternative to traditional non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of post-operative pain.

Keywords: COX-2 inhibitor; arthroplasty; lumiracoxib; naproxen; post-operative pain; selective cyclooxygenase-2 inhibitor

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1399-6576.2005.00782.x

Affiliations: 1: Toronto Western Hospital, University Health Network, Toronto, ON, 2: Chronic Pain Center, Calgary Health Region, Calgary, AB, Canada, 3: Capstone Clinical Trials Inc., 4: Alabama Orthopedic Center, Capstone Clinical Trials Inc., Birmingham, AL, and 5: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Publication date: November 1, 2005

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more